Ciro Franzese, Director of Radiation Oncology Unit at Humanitas San Pio X, Associate Professor at Humanitas University, shared on LinkedIn:
“What if SBRT could represent an additional line of treatment in oligometastatic RCC?
Pleased to share our new study published in European Urology Open Science, exploring the role of SBRT as an alternative to switching systemic therapy in oligoprogressive renal cell carcinoma.
Our exploratory analysis supports the concept of SBRT as a potential additional local treatment line, allowing selected patients to maintain an otherwise effective systemic therapy while targeting resistant disease.”
Title: Oligoprogressive Renal Cell Carcinoma Treated with Stereotactic Body Radiation Therapy Versus Switching to a New Systemic Therapy
Authors: Ciro Franzese, Matteo Perrino, Nadia Cordua, Fabio De Vincenzo, Raffaella Lucchini, Marta Aliprandi, Lorenzo Lo Faro, Luigi Cecchi, Luciana Di Cristina, Alessandro Bertocchi, Anna Bertolini, Antonio Federico, Federica Borea, Laura Giordano, Marta Scorsetti, Paolo Andrea Zucali
You can also read:
